AI-generated summary
The authors examined psychopharmacologic medication use in 553 patients with seasonal affective disorder who had been treated with bright light therapy. About 49 percent received psychopharmacologic treatment and 35.4 percent received antidepressants, which the authors read as suggesting bright light therapy does not suffice as the only antidepressant regimen for all patients. The study was a clinical sample review, so it does not directly measure treatment effectiveness.
- Participants
- 553
- Who or what was studied
- Patients with seasonal affective disorder treated with bright light therapy in a clinical sample
- Limits stated in the abstract
- The abstract describes a clinical sample review of medication use and does not report outcome data that would directly assess effectiveness.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Bright light therapy. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.